Women’s health, spanning fertility and reproductive endocrinology, maternal-fetal medicine, gynecologic conditions such as endometriosis, fibroids, and polycystic ovary syndrome, menopause, and contraception, has long attracted less research funding and venture capital than its disease burden would predict. That gap is narrowing as new biology, better diagnostics, and a generation of clinician-founders make the category investable. The science is genuinely hard, particularly around clinical trials, because pregnant and lactating populations were historically excluded from drug development, leaving real safety and dosing gaps that a new wave of maternal-fetal pharmacology is starting to fill. For a pre-seed investor like Sonnerie, the opportunity sits at the intersection of underexplored biology, a large and durable patient population, and university labs that have quietly built some of the deepest datasets in the field.
What counts as women’s health as an investment category?
Women’s health is not a single therapeutic area, it is a bundle of distinct biological systems that happen to share a regulatory and clinical history. In practice, the category spans fertility and reproductive endocrinology, including ovarian reserve, in vitro fertilization support, and hormonal signaling disorders, maternal-fetal health across pregnancy, labor, and postpartum recovery, gynecologic conditions such as endometriosis, uterine fibroids, and polycystic ovary syndrome, the menopause transition and its downstream cardiometabolic and bone effects, and contraception across hormonal and non-hormonal modalities.
Because the underlying biology is so varied, a serious investor in this space has to underwrite reproductive endocrinology, immunology, and cardiometabolic risk as separate scientific problems that happen to converge on the same patient. That breadth is precisely why the category rewards deep science over a single consumer-facing app or wellness product, and why the strongest opportunities tend to originate in academic labs that have spent years mapping one piece of that biology.
Why has women’s health been historically underinvested relative to disease burden?
Conditions like endometriosis and fibroids affect a substantial share of women of reproductive age, yet for decades attracted a smaller share of research funding than conditions of comparable prevalence. Diagnostic delay has been a persistent feature of the category, people with endometriosis symptoms have long reported years passing between symptom onset and diagnosis, a pattern public-health and clinical literature has documented repeatedly, and one that reflects both limited diagnostic tooling and a broader research gap rather than any single point of failure.
Part of the historical underinvestment traces back to clinical trial design. Regulatory caution after mid-twentieth-century drug safety failures led to the broad exclusion of pregnant people, and often all women of reproductive potential, from early-phase drug development for much of the late twentieth century. That caution was well-intentioned, but it had a compounding effect, fewer trials meant fewer approved therapies labeled for use in pregnancy or across the menstrual cycle, which in turn meant less commercial incentive to study female-specific biology, which meant less basic science funding, and the cycle reinforced itself.
Venture capital followed research funding rather than leading it. Institutional generalist funds without a life-sciences or clinical mandate tended to pattern-match women’s health to consumer wellness rather than to hard biology, which meant that some of the most scientifically rigorous companies in the category were underfunded relative to comparably novel biology in oncology or immunology.
What changed, why is capital moving into the category now?
Several forces are converging. Basic science has caught up: better understanding of endometrial and placental biology, the immune-endocrine crosstalk implicated in endometriosis, and the metabolic signaling behind polycystic ovary syndrome has given founders real mechanistic targets rather than symptom management alone. A generation of clinician-scientists trained in reproductive endocrinology, maternal-fetal medicine, and gynecologic surgery is now old enough to found companies, and operators who scaled consumer health, diagnostics, and biotech businesses elsewhere are choosing to apply that experience here.
Employers, health plans, and government payers have also started treating fertility benefits, maternal health outcomes, and menopause care as measurable cost and workforce issues rather than niche benefits, which has created a commercial pull that did not exist a decade ago. Regulators have moved in parallel, guidance in the United States has increasingly encouraged rather than discouraged the inclusion of pregnant and lactating populations in appropriately designed studies, narrowing one of the structural barriers described above.
None of this means the category is now overfunded or that every women’s health company deserves a premium valuation. It means the entry price for genuine scientific insight has come down at exactly the stage, pre-seed and seed, where Sonnerie operates.
What are the core clinical areas and their unmet needs?
Each area within women’s health carries a distinct unmet need, and a credible spinout usually maps cleanly onto one of them rather than promising to address all of them at once.
- Fertility and reproductive endocrinology: ovarian reserve assessment remains imprecise, and much of in vitro fertilization practice still relies on empirical protocols rather than mechanistic biomarkers of embryo viability or endometrial receptivity.
- Maternal-fetal health: preeclampsia, preterm labor, and postpartum hemorrhage remain leading drivers of maternal morbidity, and clinicians still lack real-time, non-invasive tools to predict which pregnancies will deteriorate before symptoms appear.
- Gynecologic conditions: endometriosis has historically been diagnosed through surgical visualization by laparoscopy, and although recent clinical guidelines have shifted toward diagnosis based on symptoms and imaging such as ultrasound and MRI, no broadly validated non-invasive biomarker yet exists, fibroids are managed largely with surgery or hormonal suppression rather than disease-modifying therapy, and polycystic ovary syndrome is treated symptom by symptom rather than at its metabolic root.
- Menopause: the transition is medically under-managed relative to its downstream cardiovascular, bone, and cognitive effects, and hormone therapy, while effective for many, is not well individualized to risk profile.
- Contraception: most non-hormonal options remain barrier methods or permanent procedures, leaving a real gap between hormonal contraception and permanent sterilization that newer biology is only beginning to address.
What is the mix of therapeutics, diagnostics, and monitoring technology in this category?
Women’s health is unusual among therapeutic categories in how evenly opportunity is spread across modalities. Therapeutics range from novel small molecules and biologics targeting endocrine and immune pathways in endometriosis and fibroids to next-generation hormonal and non-hormonal contraceptives and disease-modifying approaches to polycystic ovary syndrome. Diagnostics are arguably the more immediately fundable opportunity in several sub-categories, because the clinical need is not always a new drug but a faster, less invasive, or earlier way to identify a condition that existing therapies could already treat if diagnosed in time, endometriosis and preeclampsia risk stratification are clear examples.
Monitoring and sensing technology is the third leg, spanning at-home hormone and ovulation tracking, continuous glucose and blood pressure monitoring adapted for pregnancy, and wearable or point-of-care tools that give clinicians the kind of longitudinal data that has simply not existed for reproductive and maternal physiology. A durable women’s health company often combines two of these three legs, for instance a diagnostic that both stratifies risk and generates the real-world evidence needed to support a therapeutic’s future label expansion into pregnancy or perimenopause.
Why are clinical trials in women’s health uniquely difficult?
For decades, regulatory guidance in the United States effectively discouraged the enrollment of women of reproductive potential, and especially pregnant and lactating people, in early clinical trials, out of legitimate concern for fetal harm following well-documented drug safety failures in the mid-twentieth century. The consequence was a durable data gap, most drugs on the market today were never studied in pregnancy at all, and prescribing decisions during pregnancy have long relied on post-marketing observational data, pregnancy exposure registries, and clinical judgment rather than controlled trial evidence.
That gap matters clinically because pregnancy changes drug pharmacokinetics substantially, plasma volume, renal clearance, and placental transfer all shift over the course of gestation, which means a dose that is safe and effective outside pregnancy may be under- or over-dosed during it. Building dedicated maternal-fetal safety and pharmacokinetic data, rather than extrapolating from non-pregnant populations, is now recognized as a distinct scientific discipline, and companies that generate this kind of data well ahead of a regulatory filing carry a real, defensible advantage.
Trial design in gynecologic conditions carries its own complications: menstrual cycle phase can confound endocrine and imaging endpoints, endometriosis staging correlates poorly with symptom severity, and many candidate biomarkers have not yet been validated across diverse patient populations. Regulators have moved toward encouraging inclusion of pregnant and reproductive-age populations in appropriately designed studies, but the underlying science, how to size a trial, choose an endpoint, and manage fetal safety monitoring, is still being built by the companies operating in this space today, which is part of what makes the intellectual property and know-how genuinely defensible.
What does a fundable pre-seed women’s health spinout look like?
At the pre-seed stage, the science has to be more differentiated than the market opportunity, because the market opportunity in women’s health is now well understood by most investors. What is not well understood, and what a university lab is uniquely positioned to have built, is a genuine mechanistic or diagnostic insight, a biomarker validated in a well-characterized patient cohort, a novel target implicated by years of bench work, or a device or algorithm trained on a dataset that a corporate competitor could not easily replicate.
The team composition matters as much as the science. The strongest spinouts in this category pair a founding scientist or clinician, often a reproductive endocrinologist, maternal-fetal medicine specialist, or reproductive immunologist, with an operator who has taken a regulated health product through development before. Pre-seed is too early for a fully built-out executive team, but it is not too early to see that the founders understand the regulatory pathway they are choosing, whether that is a drug, a diagnostic, or a device, and have a credible, capital-efficient plan to generate the first proof point that de-risks the next round.
Capital efficiency is not optional in this category. Because trials involving pregnant or reproductive-age populations carry real regulatory and safety overhead, the most fundable pre-seed companies design their first year or two around a specific, answerable question, a validated biomarker, a completed first-in-human safety cohort, a diagnostic accuracy study against a defined clinical comparator, rather than a broad platform claim that cannot be tested cheaply.
How does Sonnerie evaluate opportunities in women’s health?
Sonnerie is a pre-seed and seed investor in healthcare and life sciences, and women’s health fits the same evaluation lens we apply across the portfolio: is there a genuine, defensible scientific signal, usually originating from a university lab, and is there an operator-led team capable of carrying that signal through the specific regulatory and clinical path the product requires. In women’s health, that means we look closely at whether the founding team understands the maternal-fetal or reproductive-endocrine trial considerations described above before they become a Series A diligence problem, and whether the underlying biology has been validated well enough to survive scrutiny from a specialist rather than a generalist reviewer.
As is true across our thesis, we tend to be an early institutional check into these companies, which means we spend more time with the underlying science and the founding team than a later-stage investor would need to. We do not make claims here about fund size, portfolio construction, or expected returns, this is a discussion of how we think about the category, not investment advice, and any founder or investor evaluating a specific opportunity should apply their own diligence and consult qualified professionals.
Frequently asked questions
What is the difference between femtech and women’s health biotech?
Femtech is a broad, consumer-facing label that has come to include everything from period-tracking apps to fertility wearables. Women’s health biotech and medtech refer more narrowly to companies developing therapeutics, diagnostics, or clinical-grade devices for reproductive, gynecologic, or maternal conditions, typically with a regulatory pathway attached. The categories overlap but are evaluated differently, one largely as a consumer product, the other as a regulated healthcare product with clinical evidence requirements.
Why were pregnant women historically excluded from clinical trials?
Regulatory guidance in the United States became notably cautious about enrolling pregnant and reproductive-age women in early-phase trials following well-documented drug safety failures in the mid-twentieth century. The intent was to protect fetal health, but the effect over decades was a persistent data gap, most approved drugs have limited or no controlled trial data in pregnancy, leaving prescribing decisions to rely on observational registries rather than randomized evidence. Regulators have since moved toward encouraging, rather than discouraging, the inclusion of pregnant and reproductive-age populations in appropriately designed studies.
Why is endometriosis so difficult to diagnose and treat?
Endometriosis diagnosis has traditionally relied on surgical visualization by laparoscopy. Recent clinical guidelines have shifted toward diagnosis based on symptoms and imaging such as ultrasound and MRI, but no broadly validated non-invasive biomarker exists yet, and symptom severity still does not correlate cleanly with disease stage. Public-health and clinical literature has repeatedly described multi-year delays between symptom onset and diagnosis. Treatment today is largely hormonal suppression or surgery rather than a therapy that addresses the underlying immune and endocrine biology, which is why the condition remains an active area of biotech research.
Does Sonnerie invest in devices and diagnostics, or only therapeutics, in women’s health?
The category spans all three, therapeutics, diagnostics, and monitoring or sensing technology, and a strong pre-seed opportunity can originate in any of them. Diagnostics are often especially fundable in women’s health because the clinical need is frequently an earlier or less invasive way to identify a condition that existing therapies could already treat if caught in time.
What makes a women’s health startup fundable at pre-seed rather than too early?
A fundable pre-seed company usually has a specific, validated scientific insight, often from years of academic research, a founding team that includes both clinical or scientific expertise and an operator who understands the relevant regulatory pathway, and a capital-efficient plan to generate one clear proof point, such as a validated biomarker or a completed safety cohort, within the first year or two.
Is menopause care a medical investment category or a consumer wellness trend?
It is both, but the more durable investment opportunity sits in the medical category. The menopause transition has measurable downstream cardiovascular, bone, and metabolic effects, and current management, largely hormone therapy, is not well individualized to a woman’s specific risk profile. Consumer-facing menopause products can be useful, but the deeper unmet need is diagnostic and therapeutic personalization, which is where academic research is currently most active.